AU2006259082B2 - Benzofuranyl derivatives as 5-HT6-receptor inhibitors - Google Patents

Benzofuranyl derivatives as 5-HT6-receptor inhibitors Download PDF

Info

Publication number
AU2006259082B2
AU2006259082B2 AU2006259082A AU2006259082A AU2006259082B2 AU 2006259082 B2 AU2006259082 B2 AU 2006259082B2 AU 2006259082 A AU2006259082 A AU 2006259082A AU 2006259082 A AU2006259082 A AU 2006259082A AU 2006259082 B2 AU2006259082 B2 AU 2006259082B2
Authority
AU
Australia
Prior art keywords
receptor
treatment
compound according
body weight
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006259082A
Other languages
English (en)
Other versions
AU2006259082A1 (en
Inventor
Patrizia Caldirola
Gary Johansson
Lori Sutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of AU2006259082A1 publication Critical patent/AU2006259082A1/en
Assigned to PROXIMAGEN LIMITED reassignment PROXIMAGEN LIMITED Request for Assignment Assignors: BIOVITRUM AB (PUBL)
Application granted granted Critical
Publication of AU2006259082B2 publication Critical patent/AU2006259082B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006259082A 2005-06-17 2006-06-15 Benzofuranyl derivatives as 5-HT6-receptor inhibitors Ceased AU2006259082B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0501383-4 2005-06-17
SE0501383 2005-06-17
US70652305P 2005-08-09 2005-08-09
US60/706,523 2005-08-09
PCT/EP2006/063249 WO2006134150A1 (en) 2005-06-17 2006-06-15 Benzofuranyl derivatives as 5-ht6-receptor inhibitors

Publications (2)

Publication Number Publication Date
AU2006259082A1 AU2006259082A1 (en) 2006-12-21
AU2006259082B2 true AU2006259082B2 (en) 2011-07-14

Family

ID=36659956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006259082A Ceased AU2006259082B2 (en) 2005-06-17 2006-06-15 Benzofuranyl derivatives as 5-HT6-receptor inhibitors

Country Status (18)

Country Link
US (1) US7582767B2 (enExample)
EP (1) EP1896460B1 (enExample)
JP (1) JP2008543813A (enExample)
KR (1) KR20080017482A (enExample)
CN (1) CN101193885B (enExample)
AU (1) AU2006259082B2 (enExample)
BR (1) BRPI0612746A2 (enExample)
CA (1) CA2610383A1 (enExample)
DE (1) DE602006008002D1 (enExample)
DK (1) DK1896460T3 (enExample)
EA (1) EA015671B1 (enExample)
ES (1) ES2330145T3 (enExample)
IL (1) IL187575A (enExample)
MX (1) MX2007015988A (enExample)
NO (1) NO20080354L (enExample)
NZ (1) NZ563510A (enExample)
WO (1) WO2006134150A1 (enExample)
ZA (1) ZA200710468B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
WO2026093435A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000828A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000828A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Also Published As

Publication number Publication date
KR20080017482A (ko) 2008-02-26
NO20080354L (no) 2008-01-17
NZ563510A (en) 2011-01-28
CN101193885B (zh) 2011-07-27
EA200800071A1 (ru) 2008-10-30
JP2008543813A (ja) 2008-12-04
WO2006134150A1 (en) 2006-12-21
EP1896460A1 (en) 2008-03-12
EP1896460B1 (en) 2009-07-22
CN101193885A (zh) 2008-06-04
EA015671B1 (ru) 2011-10-31
US20060293361A1 (en) 2006-12-28
ES2330145T3 (es) 2009-12-04
MX2007015988A (es) 2008-03-07
DE602006008002D1 (de) 2009-09-03
BRPI0612746A2 (pt) 2010-11-30
IL187575A (en) 2012-12-31
DK1896460T3 (da) 2009-11-16
US7582767B2 (en) 2009-09-01
IL187575A0 (en) 2008-03-20
AU2006259082A1 (en) 2006-12-21
HK1112918A1 (en) 2008-09-19
CA2610383A1 (en) 2006-12-21
ZA200710468B (en) 2009-04-29

Similar Documents

Publication Publication Date Title
US20060148818A1 (en) Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
US20060142269A1 (en) New compounds
Audinot et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors
US5021421A (en) 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
RU2449990C2 (ru) Индолы в качестве модуляторов 5-ht6
ZA200403207B (en) Therapeutic quinolone compounds with 5-HT-antagonistic properties.
JP2005511569A (ja) ５−ｈｔ−アンタゴニスト特性を有する治療用キノロン化合物
KR20090019894A (ko) 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법
EP2567698B1 (en) GPR 17 agonists and screening assay
EP1896460B1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
CA2545506A1 (en) Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
NO180486B (no) Nye indolforbindelser og anvendelse av disse i farmasöytiske preparater
US7820675B2 (en) Benzofuran compounds
JP2015214527A (ja) イミダゾール誘導体
TW568786B (en) A combination, pharmaceutical formulation, and kit for use in the treatment of affective disorders
WO2006062481A1 (en) New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
HK1112918B (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
JP2003519229A (ja) 新規ヘテロアリール誘導体、その製造方法及びその使用方法
JP5044562B2 (ja) オキセピン誘導体
KR20070020373A (ko) 5-ＨＴ6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로｛피페리딘-2,7'-피롤로[3,2-ｂ]피리딘｝ 유도체 및 신규한 인돌 유도체
HUP9903913A2 (hu) Szelektív dopamin D4 receptor ligandum troponil-piperazinok, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ZA200602756B (en) Novel tetraydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor-related disorders
CN1821236B (zh) 治疗性杂环化合物
EP1897876A2 (en) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PROXIMAGEN LIMITED

Free format text: FORMER APPLICANT(S): BIOVITRUM AB (PUBL)

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired